Treatment of the skin manifestations of Darier's disease by the topical application of COX-2 inhibitors

Treatment of the skin manifestations of Darier's disease by the topical application of COX-2 inhibitors - Treatment of Darier's disease by the topical application of COX-2 inhibitors

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015905

Enrollment

Registered

2014-12-25

Start date

2014-12-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Darier&#39

Interventions

Topical application of 1% diclofenac sodium gel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients of Darier's disease diagnosed by clinical manifestation and pathological finding

Exclusion criteria

Exclusion criteria: 1) Patients without disease notification 2) Patients who do not join "Development of the genetic diagnosis system of congenital and Inherited skin disorders (UMIN000009851)" 3) Aspirin-induced asthma patients 4) Patients with diclofenac sodium allergy 5) Pregnant women

Design outcomes

Primary

Measure	Time frame
Improvement of skin manifestations which are evaluated by Psoriasis Area and Severity Index score after 3-month treatment	—

Secondary

Measure	Time frame
Safety evaluation: Common terminology criteria for adverse events v4.0 grade 3-5 Therapy evaluation: Pathological findings and level of expression of ATP2A2 after 3-month treatment	—

Countries

Japan

Contacts

Public ContactAkiharu Kubo

Keio University School of Medicine Department of Dermatology

akiharu@keio.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Treatment of the skin manifestations of Darier&#39;s disease by the topical application of COX-2 inhibitors